Cat. No.: HY-B0320A

Cromolyn disodium

(Synonyms: Cromoglycate disodium; Cromoglicic acid disodium; FPL-670)

11 Cited Publications

Customer Review

Based on 11 publication(s) in Google Scholar

Cromolyn (Cromoglycate) disodium is an orally active GSK-3β inhibitor with an IC₅₀ of 2.0 μM. Cromolyn disodium is also a mast cell stabilizer that can inhibit the release of mediators from mast cells, regulate reflex bronchoconstriction, and reduce non-specific bronchial hyperreactivity, and Cromolyn disodium can be used in the research of bronchial asthma. In addition, Cromolyn disodium has multiple activities such as anti-inflammatory, anti-allergic, anti-histamine, anti-cancer, and neuroprotective effects.

For research use only. We do not sell to patients.

Purity: 99.98%
CAS No.: 15826-37-6
Formula: C₂₃H₁₄Na₂O₁₁
Molecular Weight:512.33

Storage:

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen)

Cromolyn disodium Chemical Structure

CAS No.: 15826-37-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (11)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All GSK-3 Isoforms :

All NF-κB Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	0.986 μM Compound: 2	Agonist activity at rat GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay Agonist activity at rat GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay	[PMID: 23713606]
CHO	EC₅₀	1.26 μM Compound: 2	Agonist activity at human GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay Agonist activity at human GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay	[PMID: 23713606]
CHO	EC₅₀	4.84 μM Compound: 2	Agonist activity at mouse GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay Agonist activity at mouse GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay	[PMID: 23713606]
LAD2	IC₅₀	>1 mM Compound: DSCG	Inhibition of human LAD2 mast cell activation assessed as compound 48/80-induced degranulation incubated for 30 mins prior to compound 48/80 challenge by beta-hexosaminidase release assay Inhibition of human LAD2 mast cell activation assessed as compound 48/80-induced degranulation incubated for 30 mins prior to compound 48/80 challenge by beta-hexosaminidase release assay	[PMID: 23617679]
Mast cell	ED₅₀	2.55 μg/mL Compound: disodium cromoglycate	Antianaphylactic activity in rat mast cells assessed as inhibition of DNP-ovalbumin-induced histamine release after 15 mins by superfusion assay Antianaphylactic activity in rat mast cells assessed as inhibition of DNP-ovalbumin-induced histamine release after 15 mins by superfusion assay	[PMID: 82617]
Mast cell	IC₅₀	3 μM Compound: 130; DSCG	Inhibition of antigen-induced release of histamine (AIR) from rat peritoneal mast cells (RMC) Inhibition of antigen-induced release of histamine (AIR) from rat peritoneal mast cells (RMC)	[PMID: 34998058]
Mast cell	IC₅₀	6.5 μM Compound: cromolyn sodium	Antiallergic activity in rat peritoneal mast cells assessed as inhibition of ovalbumin-induced histamine release after 15 mins Antiallergic activity in rat peritoneal mast cells assessed as inhibition of ovalbumin-induced histamine release after 15 mins	[PMID: 88523]
RBL-2H3	IC₅₀	1540 μM Compound: DSCG	Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge	[PMID: 14510616]

In Vitro

Cromolyn (0-100 μM; 3-10 min) disodium can inhibit IgE- and antigen-induced degranulation and PGD₂ synthesis in rat peritoneal mast cells^[1].
Cromolyn (0-100 μM; 0-72 h) disodium can block S100P-promoted cell proliferation, invasion, and increased NF-κB activity in Panc-1 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cromolyn (10 mg/kg; intravenous injection; single dose) disodium can significantly inhibit mast cell activation in IgE-dependent PCA by reducing Evans blue extravasation and completely inhibit antigen-induced plasma histamine increase in PSA in rats^[1].
Cromolyn (5 mg/kg; intraperitoneal injection; 5 weeks) disodium has anti-tumor activity in a mouse model of pancreatic cancer^[2].
Cromolyn (6.3 mg/kg; intraperitoneal injection; 5 times a week; from postnatal day 60 until euthanasia) disodium has an ameliorative effect in a model of amyotrophic lateral sclerosis^[3].
Cromolyn (1-3.15 mg/kg; intraperitoneal injection; 3 times a week; 12 weeks) disodium has a neuroprotective effect in a mouse model of Alzheimer's disease^[4].
Cromolyn (1.43-5.72 mg/kg; intraperitoneal injection; 1 month) disodium has a hypoglycemic effect in mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male CB17 scid mice aged 4 weeks old treated BxPC-3 and MPanc-96 cells^[2]
Dosage:

5 mg/kg
Administration:

Intraperitoneal injection; 5 weeks
Result:

Significantly reduced tumor burden.
Reduced lung metastasis in the BxPC-3 model and both liver and lung metastases in the MPanc-96 model.
Had no effect on body weight.

Animal Model:

SOD1^G93A mice^[3]
Dosage:

6.3 mg/kg
Administration:

Intraperitoneal injection; 5 times a week; from postnatal day 60 until euthanasia
Result:

Delays disease onset.
Improved motor deficits in the PaGE task.
Increased survival of lumbar spinal cord motor neurons, decreased denervation at the neuromuscular junction.
Reduced pro-inflammatory cytokine and chemokine levels in the spinal cord and plasma.
Decreased mast cell degranulation in the tibialis anterior muscle.

Animal Model:

APP^Swedish expressing Tg2576 mice^[4]
Dosage:

1 and 3.15 mg/kg
Administration:

Intraperitoneal injection; 3 times a week; 12 weeks
Result:

Reduced the levels of Aβ40 and Aβ42 in brain TBS-insoluble fractions.
Increased the level of Aβ38.
Promoted the phagocytosis of β-amyloid by microglia.

Animal Model:

Normal Balb/c mice, chronic type II diabetic Balb/c mice, and chronic obese Balb/c mice^[5]
Dosage:

1.43, 2.86 and 5.72 mg/kg
Administration:

Intraperitoneal injection; 1 month
Result:

Dose-dependently reducted blood glucose, body weight, and resistin levels.
Increased liver glycogen, insulin, C-peptide, and adiponectin levels in mice.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 15826-37-6
Appearance Solid
Molecular Weight 512.33
Formula C₂₃H₁₄Na₂O₁₁
Color White to off-white
SMILES

OC(COC1=C2C(C=C(C(O[Na])=O)OC2=CC=C1)=O)COC3=C4C(C=C(C(O[Na])=O)OC4=CC=C3)=O
Synonyms

Cromoglycate disodium; Cromoglicic acid disodium; FPL-670
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen)

Publications (11)

All In Vivo Efficacy StudyCell Proliferation/Viability AssayIHC

Sort by:

Journal Impact Factor

Cancer Cell

Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer. [Abstract]

2025 Mar 10;43(3):446-463.e7. PMID: 39919737

Cromolyn disodium purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Mar 10;43(3):446-463.e7. [Abstract]

Cromolyn disodium (DSCG: 10 mg/kg). Experimental workflow and tumor growth of the murine 4T1 breast tumor model. Data on day 15 were presented.

Cromolyn disodium purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2025 Mar 10;43(3):446-463.e7. [Abstract]

Cromolyn disodium (DSCG: 10 mg/kg). GSVA scores of immune cell subsets after different treatments in the murine 4T1 breast tumor model.
Nat Commun

S100P is a ferroptosis suppressor to facilitate hepatocellular carcinoma development by rewiring lipid metabolism. [Abstract]

2025 Jan 8;16(1):509. PMID: 39779666

Cromolyn disodium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 8;16(1):509. [Abstract]

Cell viability of HT1080 S100P OE cells pretreated with indicated concentrations of Cromolyn disodium for 12 h and then treated with RSL3 (200 nM) for 6 h.
Pharmacol Res

Sinomenine-induced histamine release-like anaphylactoid reactions are blocked by tranilast via inhibiting NF-κB signaling. [Abstract]

2017 Nov;125(Pt B):150-160. PMID: 28867637

Cromolyn disodium purchased from MedChemExpress. Usage Cited in: Pharmacol Res. 2017 Nov;125(Pt B):150-160. [Abstract]

The IL-33 production in different treatment groups is determined in rat skin by immunohistochemistry assay.
J Med Chem

Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors. [Abstract]

2021 Oct 14;64(19):14344-14357. PMID: 34547896
J Invest Dermatol

MRGPRX2-Mediated Mast Cell Activation Promotes Malignant Progression of Cutaneous Squamous Cell Carcinoma through IL-17A Release. [Abstract]

2025 Nov 4:S0022-202X(25)03517-1. PMID: 41197765
Int J Mol Sci

Bile Canalicular Bitter Taste Receptors Inhibit β-Adrenergic Receptor-Induced Lipolysis in Steatotic Hepatocytes. [Abstract]

2026 Apr 2;27(7):3226. PMID: 41977407
Int Immunopharmacol

Edaravone attenuates cerebral inflammation by inhibiting mast cells degranulation via ROS/STIM1 signaling pathway in HIE model. [Abstract]

2025 May 19:159:114880. PMID: 40394799
Int J Mol Sci

Pro-Tumorigenic Effect of Continuous Cromolyn Treatment in Bladder Cancer. [Abstract]

2025 Feb 14;26(4):1619. PMID: 40004083
J Inflamm Res

Astragalus membranaceus and Salvia miltiorrhiza Inhibit Tryptase/PAR2-Mediated Mast Cells - Peritoneal Mesothelial Cells Crosstalk to Ameliorate Peritoneal Fibrosis. [Abstract]

2026 May 11:19:577472. PMID: 42147796
Mol Biol Rep

Disodium cromoglycate restricts human tau hyperphosphorylation and manifestation of associated phenotypes by inhibiting GSK3β activity in Drosophila disease models. [Abstract]

2026 Apr 7;53(1):589. PMID: 41945164
Res Sq

2025 Apr 08.

Solvent & Solubility

In Vitro:

H₂O : 50 mg/mL (97.59 mM; Need ultrasonic)

DMSO : 25 mg/mL (48.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9519 mL

9.7593 mL

19.5187 mL

5 mM

0.3904 mL

1.9519 mL

3.9037 mL

10 mM

0.1952 mL

0.9759 mL

1.9519 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light, stored under nitrogen). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 50 mg/mL (97.59 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Oka T, et al. Evidence questioning cromolyn's effectiveness and selectivity as a 'mast cell stabilizer' in mice. Lab Invest. 2012 Oct;92(10):1472-82. [Content Brief]

[2]. Arumugam T, et al. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst. 2006 Dec 20;98(24):1806-18. [Content Brief]

[3]. Granucci EJ, et al. Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis. Sci Rep. 2019 Nov 27;9(1):17728. [Content Brief]

[4]. Zhang C, et al. Cromolyn Reduces Levels of the Alzheimer's Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis. Sci Rep. 2018 Jan 18;8(1):1144. [Content Brief]

[5]. Motawi TM, et al. Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation. J Biochem Mol Toxicol. 2013 Sep;27(9):425-36. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	1.9519 mL	9.7593 mL	19.5187 mL	48.7967 mL
	5 mM	0.3904 mL	1.9519 mL	3.9037 mL	9.7593 mL
	10 mM	0.1952 mL	0.9759 mL	1.9519 mL	4.8797 mL
	15 mM	0.1301 mL	0.6506 mL	1.3012 mL	3.2531 mL
	20 mM	0.0976 mL	0.4880 mL	0.9759 mL	2.4398 mL
	25 mM	0.0781 mL	0.3904 mL	0.7807 mL	1.9519 mL
	30 mM	0.0651 mL	0.3253 mL	0.6506 mL	1.6266 mL
	40 mM	0.0488 mL	0.2440 mL	0.4880 mL	1.2199 mL
H₂O	50 mM	0.0390 mL	0.1952 mL	0.3904 mL	0.9759 mL
	60 mM	0.0325 mL	0.1627 mL	0.3253 mL	0.8133 mL
	80 mM	0.0244 mL	0.1220 mL	0.2440 mL	0.6100 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Cromolyn disodium

11 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Cromolyn disodium

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Antidepressant Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

FDA Kinase Inhibitor Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Cromolyn disodium

All GSK-3 Isoforms

All NF-κB Isoforms

Biological Activity

Chemical Information

Publications (11)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Cromolyn disodium Related Classifications